The DOI matches its Crossref record; 32 of the 34 references it cites were found in a registry or an index.
NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice
Open accessAbstract
Alzheimer’s disease is the world’s most common dementing illness. Deposition of amyloid-β peptide drives cerebral neuroinflammation by activating microglia. Indeed, amyloid-β activation of the NLRP3 inflammasome in microglia is fundamental for interleukin-1β maturation and subsequent inflammatory events. However, it remains unknown whether NLRP3 activation contributes to Alzheimer’s disease in vivo. Here we demonstrate strongly enhanced active caspase-1 expression in human mild cognitive impairment and brains with Alzheimer’s disease, suggesting a role for the inflammasome in this neurodegenerative disease. Nlrp3−/− or Casp1−/− mice carrying mutations associated with familial Alzheimer’s disease were largely protected from loss of spatial memory and other sequelae associated with Alzheimer’s disease, and demonstrated reduced brain caspase-1 and interleukin-1β activation as well as enhanced amyloid-β clearance. Furthermore, NLRP3 inflammasome deficiency skewed microglial cells to an M2 phenotype and resulted in the decreased deposition of amyloid-β in the APP/PS1 model of Alzheimer’s disease. These results show an important role for the NLRP3/caspase-1 axis in the pathogenesis of Alzheimer’s disease, and suggest that NLRP3 inflammasome inhibition represents a new therapeutic intervention for the disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Rat research has identified the NLRP3-ASC inflammasome as a major mechanism through which microglia may drive pathological features of AD [92,93,94].”
From The Role of Cortisol in Chronic Stress, Neurodegenerative Diseases, and Psychological Disorders (2023) · cites this paper as [92]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Both beta-amyloids and tau can activate the NLRP3-ASC inflammasome within microglia [92,93].”
From The Role of Cortisol in Chronic Stress, Neurodegenerative Diseases, and Psychological Disorders (2023) · cites this paper as [92]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The nucleotide-binding oligomerization domain-like receptor, pyrin domain-containing 3 (NLRP3), within microglia recruits the adaptor protein apoptosis-associated speck-like protein containing a C-terminal caspase recruitment domain (ASC) to form an inflammasome complex.”
From The Role of Cortisol in Chronic Stress, Neurodegenerative Diseases, and Psychological Disorders (2023) · cites this paper as [92]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In APP/PS1 mice model, NLRP3 knockout reduced Aβ deposition by enhancing phagocytic clearance capacity and increasing extracellular Aβ degradation by insulin- degrading enzyme (IDE).354”
From Role of neuroinflammation in neurodegeneration development (2023) · cites this paper as [354]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The activation of hippocampal NLRP3 inflammasome-mediated pyroptosis is associated with neuronal damage, cognitive decline, and neuronal death (Hanslik & Ulland, 2020; Heneka et al., 2013; Ising et al., 2019; Venegas et al., 2017).”
From Picroside II Alleviates the Progression of Alzheimer’s Disease via the NLRP3/Caspase-1/GSDMD Pathway (2025) · cites this paper as Heneka et al., 2013
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“NLRP3 or caspase-1 knockdown in AD mouse models has yielded promising results in decreasing Aβ accumulation, improving spatial memory, and alleviating other AD-related symptoms (Heneka et al., 2013).”
From Picroside II Alleviates the Progression of Alzheimer’s Disease via the NLRP3/Caspase-1/GSDMD Pathway (2025) · cites this paper as Heneka et al., 2013
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Ablation of Nlrp3 or Casp1 in APP/PS1 mice rescued spatial memory and behavioral deficits, LTP suppression and spine loss observed in these mice [77].”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [77]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, another study reported strongly increased levels of active caspase-1 in early-onset AD and LOAD patients as well as in MCI individuals [77].”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [77]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“This inflammasome complex is responsible for the production of IL-1 beta, which is a proinflammatory cytokine.”
From The Role of Cortisol in Chronic Stress, Neurodegenerative Diseases, and Psychological Disorders (2023) · cites this paper as [92]
The cited source says what the claim attributes to it.
In the citing paper
“IL-1 beta was shown to exacerbate tau pathologies [97] and reduce microglial phagocytic activity [92,93,94].”
From The Role of Cortisol in Chronic Stress, Neurodegenerative Diseases, and Psychological Disorders (2023) · cites this paper as [92]
The cited source says what the claim attributes to it.
In the citing paper
“Furthermore, microglial function may also be of relevance to cognitive performance, as suggested by recent experimental data, which showed that improved microglial clearance was protective in terms of memory function (17).”
From SUCLG2 identified as both a determinator of CSF Aβ1–42 levels and an attenuator of cognitive decline in Alzheimer's disease (2014) · cites this paper as [17]
The cited source says what the claim attributes to it.
In the citing paper
“Proinflammatory environments and signalling are a prominent observation in AD brain pathology [39].”
From Heterozygous expression of the Alzheimer’s disease-protective PLCγ2 P522R variant enhances Aβ clearance while preserving synapses (2022) · cites this paper as [39]
The cited source says what the claim attributes to it.
In the citing paper
“Inhibiting or downregulating the NLRP3 inflammasome ameliorates AD neuropathology in animal models, which opens up a therapeutic avenue for modulators of NLRP3 activation in AD.”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [77]
The cited source says what the claim attributes to it.
In the citing paper
“APP/PS1/Nlrp3−/− and APP/PS1/Casp1−/− mice also displayed decreased Aβ plaque deposition, suggesting that NLRP3 inflammasome activation impairs microglial capacity to clear Aβ [77].”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [77]
The cited source says what the claim attributes to it.
In the citing paper
“APP/PS1/Nlrp3−/− and APP/PS1/Casp1−/− mice also displayed decreased Aβ plaque deposition, suggesting that NLRP3 inflammasome activation impairs microglial capacity to clear Aβ [77].”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [77]
The cited source says what the claim attributes to it.
In the citing paper
“The decreased plaque deposition was also related to increased levels of the proteolytic enzyme insulin-degrading enzyme (IDE) [77], previously reported to degrade Aβ [83].”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [77]
The cited source says what the claim attributes to it.
In the citing paper
“NLRP3 deficiency reduces amyloid deposition and rescues memory deficits in the APP/PS1 model of AD [18].”
From 25-Hydroxycholesterol amplifies microglial IL-1β production in an apoE isoform-dependent manner (2020) · cites this paper as [18]
In the citing paper
“One of the key biological functions of CASP1 is the cleavage of prointerleukin-1β (IL-1β) into the mature biological active cytokine, which is largely overexpressed in brains of patients with AD.44”
From APOE*E2 allele delays age of onset in PSEN1 E280A Alzheimer’s disease (2016) · cites this paper as [44]
In the citing paper
“Preclinical studies support the concept that CASP1-directed increase of IL-1β can augment the deposition of β-amyloid within the brain to worsen Alzheimer's symptoms.44”
From APOE*E2 allele delays age of onset in PSEN1 E280A Alzheimer’s disease (2016) · cites this paper as [44]
In the citing paper
“CASP1, an essential component of NLPR3 inflammasomes, encodes a cysteine protease that is largely overexpressed in brains of patients with AD.44”
From APOE*E2 allele delays age of onset in PSEN1 E280A Alzheimer’s disease (2016) · cites this paper as [44]
In the citing paper
“Notably, Aβ also can activate NF-κB signaling and the NLRP3-ASC inflammasome [426, 427], suggesting that Aβ and tau share common mechanisms in microglia activation.”
From Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease (2020) · cites this paper as [427]
In the citing paper
“The NLRP3 inflammasome is critical for maturation of IL-1β, and loss of NLRP3 in APP/PS1 decreased amyloid burden (131).”
From Microglia in Alzheimer's disease (2017) · cites this paper as [131]
In the citing paper
“Microglia express multiple receptors that can bind Aβ and trigger inflammation, such as CD36 (105), TLR2, TLR4, TLR6 (17), and NLRP3 (106)”
From Microglia Function in the Central Nervous System During Health and Neurodegeneration (2017) · cites this paper as [106]
In the citing paper
“NLRP3 and caspase-1 genetic deletion results in decreased Aβ deposition, reduced IL-1β release from microglia and improved cognitive performance in APPPS1 mice (Heneka et al., 2013).”
From Alzheimer Disease: An Update on Pathobiology and Treatment Strategies (2019) · cites this paper as Heneka et al., 2013
In the citing paper
“Toll-like receptors and NOD-like receptors have been previously implicated in the microglia response to Aβ accumulation and shown to mediate an inflammatory response that contributes to pathology”
From TREM2 Maintains Microglial Metabolic Fitness in Alzheimer’s Disease (2017) · cites this paper as Heneka et al., 2013
In the citing paper
“ITGAM/CD11b (or CR3A), is a cell surface receptor involved in activation, migration and phagocytosis of immune cells, so much so that ITGAM/CD11b is used as a marker of activated microglia (Matsuoka et al., 2001; Heneka et al., 2013; Kamphuis et al., 2016).”
From Genetic variability in response to amyloid beta deposition influences Alzheimer’s disease risk (2019) · cites this paper as Heneka et al., 2013
In the citing paper
“Animal studies confirmed this significant involvement of NLRP activation, as APP/PS1 mice, lacking the expression of ASC, caspase-1, or NLRP3 had significantly reduced hippocampal and cortical amyloid plaque deposition and ameliorated disease outcome (229, 230).”
From The gut-brain axis: how microbiota and host inflammasome influence brain physiology and pathology (2020) · cites this paper as [230]
In the citing paper
“Recently, an alternative pathway has been described for intracellular signaling produced by the binding of Aβ to microglial cells, activating NLRP3 inflammasome (Heneka et al., 2013; Sheedy et al., 2013).”
From The role of microglia in retinal neurodegeneration: Alzheimer’s disease, parkinson, and glaucoma. (2017) · cites this paper as Heneka et al., 2013
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A synaptic model of memory: long-term potentiation in the hippocampus
Bliss, T. V. P., & Collingridge, G. L. (1993) · Nature · doi:10.1038/361031a0 · Cited by 11,566
The NALP3 inflammasome is involved in the innate immune response to amyloid-β
Halle, A., Hornung, V., Petzold, G. C., Stewart, C. R., Monks, B. G., Reinheckel, T., Fitzgerald, K. A., Latz, E., Moore, K. J., & Golenbock, D. T. (2008) · Nature Immunology · doi:10.1038/ni.1636 · Cited by 2,441
Self-citationThe Inflammasomes: Guardians of the Body
Martinon, F., Mayor, A., & Tschopp, J. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132715 · Cited by 2,436
Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease
Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., Yarasheski, K. E., & Bateman, R. J. (2010) · Science · doi:10.1126/science.1197623 · Cited by 2,078
Li, P., Allen, H., Banerjee, S., Franklin, S., Herzog, L., Johnston, C. G., McDowell, J., Paskind, M. P., Rodman, L., Salfeld, J. G., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90490-5 · Cited by 1,408
Microglial Dysfunction and Defective β-Amyloid Clearance Pathways in Aging Alzheimer's Disease Mice
Hickman, S. E., Allison, E. K., & El Khoury, J. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.0616-08.2008 · Cited by 1,329 · cited 1×
“Cytokines, including IL-1 β , were found to impair microglial clearance functions 16,17 .”
Bevins, R. A., & Besheer, J. (2006) · Nature Protocols · doi:10.1038/nprot.2006.205 · Cited by 1,278
Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3
Kanneganti, T., Özören, N., Body–Malapel, M., Amer, A. O., Park, J., Franchi, L., Whitfield, J. R., Barchet, W., Colonna, M., Vandenabeele, P., et al. (2006) · Nature · doi:10.1038/nature04517 · Cited by 1,149
Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice
Chapman, P. F., White, G. L., Jones, M. W., Cooper-Blacketer, D., Marshall, V. J., Irizarry, M., Younkin, L., Good, M. A., Bliss, T. V. P., Hyman, B. T., et al. (1999) · Nature Neuroscience · doi:10.1038/6374 · Cited by 946
El Khoury, J., Toft, M., Hickman, S. E., Means, T. K., Terada, K., Geula, C., & Luster, A. D. (2007) · Nature Medicine · doi:10.1038/nm1555 · Cited by 915
Flagged first, then by citations
2 of the 34 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 701–800 of 1,031
Inflammasomes: Mechanisms of Action and Involvement in Human Diseases
Bulté, D., Rigamonti, C., Romano, A., & Mortellaro, A. (2023) · Cells · doi:10.3390/cells12131766 · Cited by 83
Immune Activation in Alzheimer Disease
Mary, A., Mancuso, R., & Heneka, M. T. (2024) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101921-035222 · Cited by 82
Self-citationIL-33 and its decoy sST2 in patients with Alzheimer’s disease and mild cognitive impairment
Saresella, M., Marventano, I., Piancone, F., La Rosa, F., Galimberti, D., Fenoglio, C., Scarpini, E., & Clerici, M. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01806-4 · Cited by 75
Malko, P., Mortadza, S. A. S., McWilliam, J., & Jiang, L. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00239 · Cited by 79
Glial Cells—The Strategic Targets in Amyotrophic Lateral Sclerosis Treatment
Filipi, T., Heřmanová, Z., Turečková, J., Vaňátko, O., & Anděrová, M. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9010261 · Cited by 76
Xiong, R., Zhou, X., Tang, Y., Wu, J., Sun, Y., Teng, J., Pan, R., Law, B. Y. K., Zhao, Y., Qiu, W., et al. (2020) · Phytotherapy Research · doi:10.1002/ptr.6849 · Cited by 78
Das, R. C., Rauf, A., Akhter, S., Islam, M. N., Emran, T. B., Mitra, S., Khan, I. N., & Mubarak, M. S. (2021) · Molecules · doi:10.3390/molecules26123696 · Cited by 79
Sharma, B., Satija, G., Madan, A., Garg, M., Alam, M. M., Shaquiquzzaman, M., Khanna, S., Tiwari, P., Parvez, S., Iqubal, A., et al. (2022) · Inflammation · doi:10.1007/s10753-022-01730-0 · Cited by 77
Functions of Astrocytes under Normal Conditions and after a Brain Disease
Vallés, S. L., Singh, S. K., Campos-Campos, J., Colmena, C., Campo-Palacio, I., Alvarez-Gamez, K., Caballero, Ó., & Jorda, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24098434 · Cited by 83
Targeting NLRP3 inflammasome for neurodegenerative disorders
Yao, J., Wang, Z., Song, W., & Zhang, Y. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02239-0 · Cited by 81
Mayer, C., Riera‐Ponsati, L., Kauppinen, S., Klitgaard, H., Erler, J. T., & Hansen, S. N. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1437939 · Cited by 80
Innate immune activation in Alzheimer’s disease
Wang, M., Miao, D., Cao, X., Tan, L., & Tan, L. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.04.20 · Cited by 75
Cellular Models and Assays to Study NLRP3 Inflammasome Biology
Zito, G., Buscetta, M., Cimino, M., Dino, P., Bucchieri, F., & Cipollina, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124294 · Cited by 80
Danger-Sensing/Patten Recognition Receptors and Neuroinflammation in Alzheimer’s Disease
Chiarini, A., Armato, U., Hu, P., & Prà, I. D. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239036 · Cited by 77
Distinct Features of Brain-Resident Macrophages: Microglia and Non-Parenchymal Brain Macrophages
Lee, E., Eo, J.-C., Lee, C., & Yu, J. (2021) · Molecules and Cells · doi:10.14348/molcells.2021.0060 · Cited by 83
Neuroinflammatory Signaling in the Pathogenesis of Alzheimer’s Disease
Uddin, M. S., Kabir, M. T., Jalouli, M., Rahman, M. A., Jeandet, P., Behl, T., Alexiou, A. T., Albadrani, G. M., Abdel‐Daim, M. M., Perveen, A., et al. (2021) · Current Neuropharmacology · doi:10.2174/1570159x19666210826130210 · Cited by 76
Parodi‐Rullán, R. M., Javadov, S. A., & Fossati, S. (2021) · Cells · doi:10.3390/cells10112903 · Cited by 75
Luo, X., Zhao, Y., Luo, Y., Lai, J., Ji, J., Huang, J., Chen, Y., Liu, Z., & Liu, J. (2024) · Clinical and Experimental Nephrology · doi:10.1007/s10157-023-02448-5 · Cited by 77
The impact of neuroinflammation on neuronal integrity
Tastan, B., & Heneka, M. T. (2024) · Immunological Reviews · doi:10.1111/imr.13419 · Cited by 81
Self-citationP2X7 as a scavenger receptor for innate phagocytosis in the brain
Gu, B. J., & Wiley, J. S. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14470 · Cited by 75
Repurposing the KCa3.1 inhibitor senicapoc for Alzheimer's disease
Jin, L., Lucente, J. D., Nguyen, H. M., Singh, V., Singh, L., Chavez, M., Bushong, T. R., Wulff, H., & Maezawa, I. (2019) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.754 · Cited by 77
AmeliMojarad, M., & AmeliMojarad, M. (2024) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14856 · Cited by 73
Gray, S. C., Kinghorn, K. J., & Woodling, N. S. (2020) · Neural Regeneration Research · doi:10.4103/1673-5374.272571 · Cited by 76
Targeting Inflammasomes to Treat Neurological Diseases
Lünemann, J. D., Malhotra, S., Shinohara, M. L., Montalbán, X., & Comabella, M. (2021) · Annals of Neurology · doi:10.1002/ana.26158 · Cited by 73
Inflammasome activation in traumatic brain injury and Alzheimer's disease
Johnson, N. H., Vaccari, J. P. D. R., Bramlett, H. M., Keane, R. W., & Dietrich, W. D. (2022) · Translational research · doi:10.1016/j.trsl.2022.08.014 · Cited by 74
Pyroptosis in development, inflammation and disease
Pan, Y., Cai, W., Huang, J., Cheng, A., Wang, M., Yin, Z., & Jia, R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.991044 · Cited by 74
The role of dopamine in NLRP3 inflammasome inhibition: Implications for neurodegenerative diseases
Possemato, E., Barbera, L. L., Nobili, A., Krashia, P., & D’Amelio, M. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101907 · Cited by 76
Microglia as Dynamic and Essential Components of the Amyloid Hypothesis
Gandy, S., & Heppner, F. L. (2013) · Neuron · doi:10.1016/j.neuron.2013.05.007 · Cited by 74
Expression of IL-1β in rhesus EAE and MS lesions is mainly induced in the CNS itself
Burm, S. M., Peferoen, L. A. N., Zuiderwijk-Sick, E. A., Haanstra, K. G., Hart, B. A. ‘., van der Valk, P., Amor, S., Bauer, J., & Bajramovic, J. J. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0605-8 · Cited by 73
Cortese, G. P., & Bürger, C. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.08.027 · Cited by 77
The NLRP3 inflammasome modulates tau pathology and neurodegeneration in a tauopathy model
Stancu, I. C., Lodder, C., Botella Lucena, P., Vanherle, S., Gutiérrez de Ravé, M., Terwel, D., Bottelbergs, A., & Dewachter, I. (2022) · Glia · doi:10.1002/glia.24160 · Cited by 72
Bulati, M., Buffa, S., Martorana, A., Gervasi, F., Camarda, C., Azzarello, D. M., Monastero, R., Caruso, C., & Colonna-Romano, G. (2015) · Journal of Alzheimer’s Disease · doi:10.3233/jad-142412 · Cited by 72
Heat Shock Proteins and Inflammasomes
Martine, P., & Rébé, C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184508 · Cited by 72
The roles of NLRP3 inflammasome-mediated signaling pathways in hyperuricemic nephropathy
Wen, L., Yang, H., Ma, L., & Fu, P. (2021) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-020-03997-z · Cited by 74
The Role of the Effects of Autophagy on NLRP3 Inflammasome in Inflammatory Nervous System Diseases
Zhao, S., Li, X., Wang, J., & Wang, H. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.657478 · Cited by 72
Dimethyl fumarate: A review of preclinical efficacy in models of neurodegenerative diseases
Majkutewicz, I. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175025 · Cited by 79
GPR120 modulates epileptic seizure and neuroinflammation mediated by NLRP3 inflammasome
Qin, Z., Song, J., Lin, A., Yang, W. L., Zhang, W., Zhong, F., Huang, L., Lü, Y., & Yu, W. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02482-2 · Cited by 76
Su, S., Wu, Y., Lin, Q. D., Zhang, L., Wang, D., & Hai, J. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02675-9 · Cited by 76
Role of Inflammasomes in Intestinal Inflammation and Crohnʼs Disease
Opipari, A. W., & Franchi, L. (2014) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000230 · Cited by 75
Lourenco, M. V., Ferreira, S. T., & Felice, F. G. D. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.03.003 · Cited by 74
Ramaswamy, V., Walsh, J. G., Sinclair, D. B., Johnson, E. S., Tang‐Wai, R., Wheatley, B. M., Branton, W. G., Maingat, F. G., Snyder, T. J., Gross, D. W., et al. (2013) · Journal of Neuroinflammation · doi:10.1186/1742-2094-10-152 · Cited by 72
Microglia Ontology and Signaling
ElAli, A., & Rivest, S. (2016) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2016.00072 · Cited by 75
Complement C5a potentiates uric acid crystal‐induced IL‐1β production
An, L., Mehta, P., Xu, L., Turman, S., Reimer, T., Naiman, B. M., Connor, J. R., Sanjuán, M. A. F., Kolbeck, R., & Fung, M. S. C. (2014) · European Journal of Immunology · doi:10.1002/eji.201444560 · Cited by 71
Targeting NLRP3-Mediated Neuroinflammation in Alzheimer’s Disease Treatment
Barczuk, J., Siwecka, N., Lusa, W., Rozpędek‐Kamińska, W., Kucharska, E., & Majsterek, I. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23168979 · Cited by 76
Targeting Microglia in Alzheimer’s Disease: Pathogenesis and Potential Therapeutic Strategies
Sun, Z., Zhang, X., So, K.-F., Jiang, W., & Chiu, K. (2024) · Biomolecules · doi:10.3390/biom14070833 · Cited by 71
Yoo, J., Lee, J., Ahn, B., Han, J., & Lim, M. H. (2025) · Chemical Science · doi:10.1039/d4sc06762b · Cited by 78
α1-antitrypsin mitigates NLRP3-inflammasome activation in amyloid β1–42-stimulated murine astrocytes
Ebrahimi, T., Rust, M. I., Kaiser, S., Slowik, A., Beyer, C., Koczulla, A. R., Schulz, J. B., Habib, P., & Bach, J. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1319-x · Cited by 72
Lv, M., Yang, S., Cai, L., Qin, L., Li, B., & Wan, Z. (2018) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201800621 · Cited by 70
The strategies of targeting the NLRP3 inflammasome to treat inflammatory diseases
Jiang, H., Gong, T., & Zhou, R. (2019) · Advances in immunology · doi:10.1016/bs.ai.2019.11.003 · Cited by 71
NLRP3 Inflammasomes in Parkinson’s disease and their Regulation by Parkin
Yan, Y., Fang, Y., Zheng, R., Pu, J., & Zhang, B. (2020) · Neuroscience · doi:10.1016/j.neuroscience.2020.08.004 · Cited by 72
Neuroimmune cleanup crews in brain injury
Bolte, A. C., & Lukens, J. R. (2021) · Trends in Immunology · doi:10.1016/j.it.2021.04.003 · Cited by 69
Feng, X., Zhan, F., Luo, D., Hu, J., Wei, G., Hua, F., & Xu, G. (2021) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2021.08.230 · Cited by 66
Rui, W., Xiao, H., Fan, Y., Ma, Z., Xiao, M., Li, S., & Shi, J. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02329-2 · Cited by 79
CD 4 T cells in immunity and immunotherapy of A lzheimer's disease
Monsonego, A., Nemirovsky, A., & Harpaz, I. (2013) · Immunology · doi:10.1111/imm.12103 · Cited by 72
Molecular and genetic inflammation networks in major human diseases
Zhao, Y., Forst, C. V., Sayegh, C. E., Wang, I., Yang, X., & Zhang, B. (2016) · Molecular BioSystems · doi:10.1039/c6mb00240d · Cited by 72
Inflammation: Bridging Age, Menopause and APOEε4 Genotype to Alzheimer’s Disease
Mishra, A., & Brinton, R. D. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00312 · Cited by 71
The Role of P2X7 Receptor in Alzheimer’s Disease
Francistiová, L., Bianchi, C., Lauro, C. D., Sebastián‐Serrano, Á., de Diego-García, L., Kobolák, J., Dinnyés, A., & Díaz-Hernández, M. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.00094 · Cited by 73
Interleukin-10 deficiency exacerbates inflammation-induced tau pathology
Weston, L. L., Jiang, S., Chisholm, D., Jantzie, L. L., & Bhaskar, K. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02211-1 · Cited by 69
Extracellular ADP augments microglial inflammasome and NF‐κB activation via the P2Y12 receptor
Suzuki, T., Kohyama, K., Moriyama, K., Ozaki, M., Hasegawa, S., Ueno, T., Saitoe, M., Morio, T., Hayashi, M., & Sakuma, H. (2019) · European Journal of Immunology · doi:10.1002/eji.201848013 · Cited by 72
Cognitive dysfunction following COVID-19 infection
Hadad, R., Khoury, J., Stanger, C., Fisher, T., Schneer, S., Ben‐Hayun, R., Possin, K. L., Valcour, V., Aharon‐Peretz, J., & Adir, Y. (2022) · Journal of NeuroVirology · doi:10.1007/s13365-022-01079-y · Cited by 82
Degechisa, S. T., Dabi, Y. T., & Gizaw, S. T. (2022) · Immunity Inflammation and Disease · doi:10.1002/iid3.647 · Cited by 69
Hoyle, C., Rivers‐Auty, J., Lemarchand, E., Vranic, S., Wang, E., Buggio, M., Rothwell, N. J., Allan, S. M., Kostarelos, K., & Brough, D. (2018) · ACS Nano · doi:10.1021/acsnano.8b03642 · Cited by 68
Wang, Z., Hu, W., Lu, C., Ma, Z., Jiang, S., Gu, C., Acuña-Castroviejo, D., & Yang, Y. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.311916 · Cited by 72
Jiang, Y., Liu, H., Green, J., Blevins, H., Guo, C., Patel, S., Halquist, M. S., McRae, M., Venitz, J., Wang, X., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01155 · Cited by 69
Circulatory miR-223-3p Discriminates Between Parkinson’s and Alzheimer’s Patients
Mancuso, R., Agostini, S., Hernis, A., Zanzottera, M., Bianchi, A., & Clerici, M. (2019) · Scientific Reports · doi:10.1038/s41598-019-45687-x · Cited by 70
Luís, J. P., Simões, C. J. V., & Brito, R. M. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031731 · Cited by 74
Zhou, Y., Zhang, S., Zhang, J., Liu, X.-L., Sun, D., Zheng, M.-T., Li, X., Niu, H., Zhang, L., Zhou, Z.-W., et al. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.344829 · Cited by 68
Ellagic Acid and Its Anti-Aging Effects on Central Nervous System
Zhu, H., Yan, Y., Jiang, Y., & Meng, X. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810937 · Cited by 69
Microglial Activation and Priming in Alzheimer’s Disease: State of the Art and Future Perspectives
Bivona, G., Iemmolo, M., Agnello, L., Sasso, B. L., Gambino, C. M., Giglio, R. V., Scazzone, C., Ghersi, G., & Ciaccio, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24010884 · Cited by 74
McManus, R. M., Komes, M. P., Griep, A., Santarelli, F., Schwartz, S., Perea, J. R., Schlachetzki, J. C. M., Bouvier, D. S., Khalil, M., Lauterbach, M., et al. (2025) · Immunity · doi:10.1016/j.immuni.2025.01.007 · Cited by 81
Self-citationYang, H. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17081041 · Cited by 78
Hippocampal Deficits in Amyloid-β-Related Rodent Models of Alzheimer’s Disease
Vyas, Y., Montgomery, J. M., & Cheyne, J. E. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00266 · Cited by 66
Inflammasome-derived cytokine IL18 suppresses amyloid-induced seizures in Alzheimer-prone mice
Tzeng, T.-C., Hasegawa, Y., Iguchi, R., Cheung, A., Caffrey, D. R., Thatcher, E. J., Mao, W., Germain, G., Tamburro, N. D., Okabe, S., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1801802115 · Cited by 67
Self-citationZhao, Z., Wang, X., Zhang, R., Ma, B., Niu, S., Di, X., Ni, L., & Liu, C. (2021) · Aging · doi:10.18632/aging.202829 · Cited by 68
Zhang, H., Jiang, W., Zhao, Y., Song, T., Xi, Y., Han, G., Jin, Y., Song, M., Bai, K., Zhou, J., et al. (2022) · Nano Letters · doi:10.1021/acs.nanolett.2c00191 · Cited by 69
The Role of Osteopontin in Microglia Biology: Current Concepts and Future Perspectives
Rosmus, D.-D., Lange, C., Ludwig, F., Ajami, B., & Wieghofer, P. (2022) · Biomedicines · doi:10.3390/biomedicines10040840 · Cited by 70
Lopes, C., Mota, S., Deus, C., Tavares, H., & Beatriz, M. (2022) · Cells · doi:10.3390/cells11152364 · Cited by 77
Madhu, L. N., Kodali, M., Upadhya, R., Rao, S., Somayaji, Y., Attaluri, S., Shuai, B., Kirmani, M., Gupta, S., Maness, N., et al. (2024) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12519 · Cited by 69
Yoon, S.-H., Kim, C., Lee, E., Lee, C., Lee, K.-S., Lee, J., Park, H., Choi, B., Hwang, I., Kim, J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-56097-1 · Cited by 78
Role of Genetic Alterations in the NLRP3 and CARD8 Genes in Health and Disease
Paramel, G. V., Sirsjö, A., & Fransén, K. (2015) · Mediators of Inflammation · doi:10.1155/2015/846782 · Cited by 66
Bezbradica, J. S., Coll, R. C., & Schroder, K. (2016) · Cellular and Molecular Immunology · doi:10.1038/cmi.2016.11 · Cited by 67
Inflammasome Involvement in Alzheimer’s Disease
Olsen, I., & Singhrao, S. K. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160197 · Cited by 66
Wang, H., Zhang, T., Huang, J., Xiang, J., Chen, J., Fu, J., & Zhao, Y. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000481753 · Cited by 66
Cardiovascular diseases, NLRP3 inflammasome, and western dietary patterns
Pavillard, L. E., Marín‐Aguilar, F., Bullón, P., & Cordero, M. D. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.03.018 · Cited by 67
Protection of MCC950 against Alzheimer's disease via inhibiting neuronal pyroptosis in SAMP8 mice
Li, J., Zhuang, L., Luo, X., Liang, J., Sun, E., & He, Y. (2020) · Experimental Brain Research · doi:10.1007/s00221-020-05916-6 · Cited by 68
Gao, Y., Li, J., Li, J., Hu, C., Zhang, L., Yan, J., Li, L., & Zhang, L. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.113997 · Cited by 65
Modulation of Glial Function in Health, Aging, and Neurodegenerative Disease
Hanslik, K. L., Marino, K. M., & Ulland, T. K. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.718324 · Cited by 69
The Role of Microglia in the Development of Neurodegenerative Diseases
Lee, J., Chun, W., Lee, H. J., Kim, S., Min, J., Kim, D.-Y., Kim, M.-O., Ryu, H. W., & Lee, S. U. (2021) · Biomedicines · doi:10.3390/biomedicines9101449 · Cited by 64
Jia, H., Liu, X., Cao, Y., Niu, H., Zhang, L., Li, R., Li, F., Sun, D., Shi, M., Wa, L., et al. (2023) · Brain Research · doi:10.1016/j.brainres.2023.148383 · Cited by 66
Mitochondria: sensors and mediators of innate immune receptor signaling
Cloonan, S. M., & Choi, A. M. K. (2013) · Current Opinion in Microbiology · doi:10.1016/j.mib.2013.05.005 · Cited by 67
Haneklaus, M., O’Neil, J. D., Clark, A. R., Masters, S. L., & O'Neill, L. A. J. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.772947 · Cited by 66
Unconjugated bilirubin induces pyroptosis in cultured rat cortical astrocytes
Feng, J., Li, M., Wei, Q., Sheng-jun, L., Song, S., & Hua, Z. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1064-1 · Cited by 65
Poff, A. M., Rho, J. M., & D’Agostino, D. P. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.01041 · Cited by 65
Update of inflammasome activation in microglia/macrophage in aging and aging‐related disease
Hu, M., Lin, Y., Zhang, B., Lu, D., Lu, Z., & Cai, W. (2019) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13262 · Cited by 67
Emerging perspectives on mitochondrial dysfunction and inflammation in Alzheimer’s disease
Yoo, S., Park, J., Kim, S., & Jung, Y. (2020) · BMB Reports · doi:10.5483/bmbrep.2020.53.1.274 · Cited by 65
Bai, N., Zhang, Q., Zhang, W., Liu, B., Yang, F., Brann, D. W., & Wang, R. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-1715-x · Cited by 65
Dissecting the Contribution of Vascular Alterations and Aging to Alzheimer’s Disease
Janota, C. S., Lemere, C. A., & Brito, M. A. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9319-7 · Cited by 70
Modulation of β-Amyloid Fibril Formation in Alzheimer’s Disease by Microglia and Infection
Brown, M. R., Radford, S. E., & Hewitt, E. W. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.609073 · Cited by 67
He, X., Xu, J., Li, G., Li, M., Li, L., Pei, Z., Zhang, L., & Hu, X. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-03072-x · Cited by 64
Pandey, G. N., Zhang, H., Sharma, A., & Ren, X. (2021) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.210016 · Cited by 68
Metadata
- Authors
- Heneka, M. T., Kummer, M. P., Stutz, A., Delekate, A., Schwartz, S., Vieira-Saecker, A., Griep, A., Axt, D., Remus, A., Tzeng, T.-C., Gelpi, E., Halle, A., Korte, M., Latz, E., & Golenbock, D. T.
- Affiliations
- University of Bonn (DE)
- Technische Universität Braunschweig (DE)
- University of Massachusetts Chan Medical School (US)
- Center of Advanced European Studies and Research (DE)
- Corresponding author
- Heneka, Michael T.
- Latz, Eicke
- Golenbock, Douglas T.
- ORCID
- Venue
- Nature
- Published
- 2012-12-19
- Volume
- 493
- Issue
- 7434
- Pages
- 674-678
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3812809
- OpenAlex
- W1993976394
- Semantic Scholar
- 3a962c33176c94bc0dd8bfea4ebe2eb83be8a01e
- Cited by
- 2,898
- References
- 34
- Citations by year
- 2026: 274 · 2025: 270 · 2024: 273 · 2023: 270 · 2022: 306 · 2021: 314 · 2020: 261 · 2019: 203 · 2018: 187 · 2017: 147 · 2016: 117 · 2015: 112 · 2014: 99 · 2013: 62
- FWCI
- 35.07
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Open Repository and Bibliography (University of Luxembourg) (submittedVersion, other-oa)
- HZI (Helmholtz Centre for Infection Research) (submittedVersion)
- The Journal of the American Medical Association (JAMA) Network (American Medical Association) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Max Planck Digital Library (submittedVersion)
- DZNE Pub (submittedVersion)
- MPG.PuRe (Max Planck Society) (submittedVersion)
- Funders
- Deutsche Forschungsgemeinschaft
- National Institutes of Health
- Genentech
- National Heart, Lung, and Blood Institute (R01HL093262)
- National Institute of General Medical Sciences (R01GM054060)
- National Institute of Allergy and Infectious Diseases (U19AI084048, R01AI083713)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- NLRP3 inflammasome, caspase-1, Alzheimer's disease, amyloid-beta, APP/PS1 mice, microglia, neuroinflammation, IL-1β, amyloid-beta clearance, spatial memory, NLRP3 knockout mice, cognitive impairment, therapeutic target
- MeSH terms
- NLR Family, Pyrin Domain-Containing 3 Protein, Aged, Aged, 80 and over, Alzheimer Disease, Animals, Behavior, Animal, Brain, Carrier Proteins, Humans, Memory, Mice, Inbred C57BL, Mice, Transgenic, Phagocytosis, Gene Expression Regulation, Enzymologic, Amyloid beta-Peptides, Caspase 1, Mice, Nitric Oxide Synthase Type II, Interleukin-1beta, Inflammasomes, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
